← 返回

为什么 CD4+ T 细胞在实体癌过继性细胞治疗中至关重要

英文原题:Why CD4+ T cells matter in adoptive cell therapy for solid cancers.

查看英文原题

Why CD4+ T cells matter in adoptive cell therapy for solid cancers.

PubMed 2026/09/22(内容时间) Immunooncol Technol

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

细胞毒性CD8+ T细胞一直是提高抗癌过继细胞疗法疗效的研究重点。

中文摘要

细胞毒性CD8+ T细胞一直是提高抗癌过继性细胞疗法疗效的研究重点。然而,新出现的证据正在强调CD4+ T细胞在这些治疗中的关键作用,包括嵌合抗原受体-T细胞。尽管已知CD4+ T细胞的存在对细胞疗法的疗效很重要,但CD4+嵌合抗原受体-T细胞发挥其有益作用的机制仍未完全清楚。在本文中,我们综述了CD4+ T细胞在过继性细胞疗法中的作用,强调了尚未被探索的研究不足领域,并提出新的方向以推进我们对其抗肿瘤潜力的理解。

展开英文摘要原文

Cytotoxic CD8+ T cells have been the focus of research efforts to improve the efficacy of anticancer adoptive cell therapies.

However, emerging evidence is highlighting the critical role of CD4+ T cells in these treatments, including chimeric antigen receptor-T cells. Although the presence of CD4+ T cells is known to be important for efficacy of cell therapies, the mechanisms by which CD4+ chimeric antigen receptor-T cells exert their beneficial effects remain incompletely understood.

In this article, we review the roles of CD4+ T cells in adoptive cell therapy, highlighting understudied areas that are yet to be explored, and propose new directions to advance our understanding of their antitumour potential.

论文信息

作者
Jegatheeson S、Scheffler C、De Bondt M、Darcy PK、Neeson PJ
单位
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.Australia
文献类型
综述
期刊
Immuno-oncology technology2026 Dec
原文标识
PubMed 42830771 · DOI 10.1016/j.iotech.2026.101615